ClinicalTrials.gg
TerminatedNCT02135354BACEUpdated Sep 5, 2018

Azithromycin for Acute Exacerbations Requiring Hospitalization

A Phase 3 interventional study of Azithromycin and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Wim Janssens. Terminated at 20 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-05.

Sponsored by Wim Janssens · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
301
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Azithromycin · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 17
301 · median 92
Started
2014
with 2 others
Phase 3
6 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
3 of 17
Wim Janssens

Among the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 3 that started in 2014, is one of 6 in phase 3, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azithromycin

Azithromycin: first FDA approval 1991 (ZITHROMAX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing azithromycin in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This project (funded by the IWT-TBM program) will organize a randomized placebo-controlled multicenter intervention trial in 500 COPD patients to study the effectiveness and safety of azithromycin therapy in the acute setting of COPD exacerbations requiring hospital admission. Although long-term use of azithromycin is proven effective to prevent exacerbations, inherent risks outweigh the benefits. By reducing the dose and duration of the azithromycin treatment and by restricting the treatment to acute periods with highest risk for treatment failure, benefits may counterbalance potential side effects, which may result in a new treatment strategy for these acute events.

The present study is designed by the services of respiratory medicine of the Leuven and Ghent University hospitals but will run in total in 17 different large hospitals in Belgium, of which 12 are located in Flanders.

Read the detailed description

In this 9 month, randomized, placebo-controlled, parallel-group, multicenter intervention trial, 500 patients will be randomly assigned (1:1 ratio) to receive either azithromycin or placebo on top of standard therapy in the acute treatment of COPD exacerbations requiring hospitalization. The study drug (azithromycin or placebo) will be initiated and uploaded within 48 hours after hospital admission (500mg once a day for 3 days) and subsequently administered for a prolonged period of 3 months at a lower maintenance dose (250mg every 2 days). An additional follow-up period of 6 months without study drug will be foreseen to study relapse after study drug withdrawal.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • AECOPD
  • Chronic Obstructive Pulmonary Disease
  • Acute exacerbation
  • Hospitalization
  • Azithromycin
  • Macrolides
  • Randomized Controlled Trial
  • Placebo
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established diagnosis of by medical doctor (based on clinical history OR pulmonary function test)
  • Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years, etc.)
  • Current hospitalization for potential infectious AECOPD treated with standard therapy
  • History of at least one exacerbation during the last year (prior to the current hospital admission) for which systemic and/or antibiotics were taken
  • at admission

Exclusion criteria

Exclusion Criteria:

  • Mechanical or non-invasive ventilation at moment of randomization (D1)
  • Long on (QTc > 450msec for males or > 470msec for females)
  • History of life-threatening arrhythmias
  • Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug
  • Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission
  • Drugs with high risk for long QT interval and torsade de pointes (amiodarone, flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)
  • Documented uncorrected severe hypokalemia (K+ \< 3.0 mmol/L) or hypomagnesemia (Mg2+ \< 0.5 mmol/L)
  • Chronic systemic (> 4 mg methylprednisolone /day for ≥ 2 months)
  • Actual use of macrolides for at least 2 weeks
  • Allergy to macrolides
  • Active cancer treatment
  • \< 3 months
  • Pregnant or breast-feeding subjects. Woman of must have a pregnancy test performed and a negative result must be documented before start of treatment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
301 participants (actual)

Study arms

  • Experimental
    Azithromycin

    N = 250 * From day 1 up to and including day 3: 500 mg azithromycin PO once a day * From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days

    Drug: Azithromycin

  • Placebo comparator
    Placebo

    N = 250 * From day 1 up to and including day 3: 500 mg placebo PO once a day * From day 4 up to and including day 90: 250 mg placebo PO once every 2 days

    Drug: Placebo

Interventions

  • * From day 1 up to and including day 3: 500 mg azithromycin PO once a day * From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days

    Also known as: Azitromcyine CF, ATC code: J01FA10

  • DrugPlacebo

    * From day 1 up to and including day 3: 500 mg placebo PO once a day * From day 4 up to and including day 90: 250 mg placebo PO once every 2 days

    Also known as: Inactive substance

06

What researchers measure

Primary outcomes

  1. Time to clinical failure

    Clinical failure is a composite endpoint as multiple clinical interventions may indicate that an initiated therapy is failing. Clinical failure is defined as the composite of death, treatment intensification (additional dose of systemic steroids, switch antibiotics for respiratory reasons or new course of systemic steroids and/or antibiotics) and step up in hospital care for respiratory reasons (from ward to ICU during index event, or from home to ward or ICU (new admission) after discharge). Primary outcome measure will also be analysed in following subgroups as an exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed between day 1 (from 1 hour after first drug intake) till day 90 (24 hours after last study drug intake)

Secondary outcomes

  1. Number of clinical failures up to Day 90 (key secondary #1)

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase)

  2. COPD Assessment Test (CAT) score at Day 90 (key secondary #2)

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase)

  3. Total days of additional/prolonged systemic steroid use at Day 90 (key secondary #3)

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase)

  4. Number of clinical failures up to Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III * ICS use vs no ICS use

    Time frame: Will be assessed on day 270 (last day of follow-up phase)

  5. Time to clinical failure up to Day 90 and up to Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  6. Time to new exacerbation within 90 and within 270 days

    A new exacerbation is defined as the composite of new course of systemic steroids and/or antibiotics, and hospitalization for respiratory reasons, all after the index event. Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  7. Number of new exacerbations up to 90 days and up to 270 days

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  8. Total days of hospital days within 90 and within 270 days

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  9. Total days in intensive care within 90 and within 270 days

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  10. Quality of Life - 5 Dimensions (EQ5D) score at Day 90 and at Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  11. COPD Assessment Test (CAT) score at Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 270 (last day of follow-up phase)

  12. Modified Medical Research Council (mMRC) score at Day 90 and Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  13. Speech, Spatial and Qualities of Hearing (SSQ5) score at Day 90 and Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  14. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) at Day 90 and Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  15. Total dose of additional/prolonged systemic steroids at Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 270 (last day of follow-up phase)

  16. Total days of additional/prolonged systemic steroid use at Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 270 (last day of follow-up phase)

  17. Total days of non-study antibiotic use at Day 90 and Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  18. Number of home physician contacts at Day 90 and Day 270

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  19. Average cost of hospitalization at Day 90 and Day 270 including the index hospitalization

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  20. Time to death within 90 and within 270 days

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  21. Time to first treatment intensification within 90 and within 270 days

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

  22. Time to first step up in hospital care for respiratory reasons within 90 and within 270 days

    Secondary outcome measure will also be analysed in following subgroups as exploratory analysis: * Male vs female * Smoker vs ex-smoker (stopped smoking \> 6 months) * GOLD A, B vs GOLD C vs GOLD D * former GOLD I, II vs III vs IV * High CRP (\> 50 mg/dL) vs low CRP (\< 50 mg/dL) * Age \> 65 years vs ≤ 65 years * Anthonissen I vs Anthonissen II vs Anthonissen III at admission * ICS use vs no ICS use

    Time frame: Will be assessed on day 90 (last day of treatment phase) and day 270 (last day of follow-up phase)

07

Study locations

20 sites
  • UZ Brussel
    Brussel, Brussel Hoofdstedelijk Gewest 1090, Belgium
  • St. Pieterziekenhuis
    Brussel, Brussels Hoofdstedelijk Gewest 1000, Belgium
  • ZNA Middelheim
    Antwerpen, Vlaanderen 2020, Belgium
  • St. Augustinus Ziekenhuis
    Antwerpen, Vlaanderen 2610, Belgium
  • Imelda Ziekenhuis
    Bonheiden, Vlaanderen 2820, Belgium
  • St. Jan Brugge Ziekenhuis
    Brugge, Vlaanderen 8000, Belgium
  • Maria Middelaresziekenhuis
    Gent, Vlaanderen 9000, Belgium
  • UZ Gent
    Gent, Vlaanderen 9000, Belgium
  • Jessa Ziekenhuis
    Hasselt, Vlaanderen 3500, Belgium
  • AZ Groeninge Ziekenhuis
    Kortrijk, Vlaanderen 8500, Belgium
  • UZ Gasthuisberg
    Leuven, Vlaanderen 3000, Belgium
  • Heilig Hart Ziekenhuis
    Roeselare, Vlaanderen 8800, Belgium
  • St. Andriesziekenhuis
    Tielt, Vlaanderen 8700, Belgium
  • CHU Charleroi
    Charleroi, Wallonië 6110, Belgium
  • Grand Hôpital de Charleroi
    Gilly, Wallonië 6060, Belgium
  • CHU Liège
    Liège, Wallonië 4000, Belgium
  • CHU Mont-Godinne
    Yvoir, Wallonië 5530, Belgium
  • Onze-Lieve-Vrouwziekenhuis
    Aalst, 9300, Belgium
  • Clinique Reine Astrid
    Malmedy, 4960, Belgium
  • Clinique Sainte-Elisabeth
    Namur, 5000, Belgium
08

References and documents

Publications

  • Vermeersch K, Belmans A, Bogaerts K, Gyselinck I, Cardinaels N, Gabrovska M, Aumann J, Demedts IK, Corhay JL, Marchand E, Slabbynck H, Haenebalcke C, Vermeersch S, Verleden GM, Troosters T, Ninane V, Brusselle GG, Janssens W; BACE trial investigators. Treatment failure and hospital readmissions in severe COPD exacerbations treated with azithromycin versus placebo - a post-hoc analysis of the BACE randomized controlled trial. Respir Res. 2019 Oct 29;20(1):237. doi: 10.1186/s12931-019-1208-6. PubMed 31665017 ↗
  • Vermeersch K, Gabrovska M, Deslypere G, Demedts IK, Slabbynck H, Aumann J, Ninane V, Verleden GM, Troosters T, Bogaerts K, Brusselle GG, Janssens W. The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2016 Mar 31;11:687-96. doi: 10.2147/COPD.S95501. eCollection 2016. PubMed 27099485 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Oct 2017, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2014
First posted
May 9, 2014
StartActual
Aug 1, 2014
Primary completionActual
Oct 2017
CompletionActual
Apr 2018
Last update
Sep 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02135354
Lead sponsor
Wim Janssens
Collaborators
Agentschap voor Innovatie door Wetenschap en Technologie
Responsible party
Wim Janssens (MD. PhD, KU Leuven) — Sponsor-investigator
First posted
May 9, 2014
Start date
Aug 1, 2014
Primary completion
Oct 2017
Completion
Apr 2018
Last update
Sep 5, 2018

Study contacts

Wim Janssens, MD. PhD
principal investigator · KU Leuven - UZ Leuven

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azithromycin

Start the discussion